SCHEMBL6984836

SCHEMBL6984836

O=C(Nc1ccc2c(c1)CCCN2)c1ccccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 10/20 0.66
NPC1 O15118 9/20 0.66
NFKB1 P19838 4/20 0.66
NFKB2 Q00653 4/20 0.66
RELA Q04206 4/20 0.66
SMN1; SMN2 Q16637 4/20 0.66
HTT P42858 2/20 0.66
TP53 P04637 2/20 0.66
GAA P10253 1/20 0.66
PLAU P00749 1/20 0.64
MAPT P10636 2/20 0.57
KDM4E B2RXH2 1/20 0.57
PIR O00625 1/20 0.53
GSK3B P49841 1/20 0.53
HSF1 Q00613 1/20 0.53
MAPK14 Q16539 4/20 0.52
KCNK3 O14649 2/20 0.50
KCNK9 Q9NPC2 1/20 0.50
KMT2A Q03164 1/20 0.49
ALDH1A1 P00352 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4716893 0.92 RAB9A (0.61) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL30847429 0.92 RAB9A (0.61) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL691153 0.84 MAPT (0.60) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL4423365 0.82 SMN1; SMN2 (0.56) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL21499352 0.81 PLAU (0.58) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL6981447 0.81 NPC1 (0.68) RAB9ANPC1SMN1; SMN2GAAPLAU
SCHEMBL5053574 0.80 PLAU (0.56) RAB9ANPC1HTTTP53GAA
SCHEMBL30464664 0.80 PLAU (0.56) RAB9ANPC1HTTTP53GAA
SCHEMBL10365448 0.80 MAP4K1 (0.65) RAB9ANPC1NFKB1NFKB2RELA
SCHEMBL31139986 0.79 PLAU (0.53) RAB9ANPC1NFKB1NFKB2RELA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0991624-B1 PHENYLALKYL DERIVATIVES WITH THROMBIN-INHIBITING EFFECT BOEHRINGER INGELHEIM PHARMA (DE) 2003-11-19 EP disclosed
US-6300342-B1 FOR THERAPY OR INHIBITING THROMBUS FORMATION; FOR THERAPY OF FIBRIN-DEPENDENT INFLAMMATORY CONDITION BOEHRINGER INGELHEIM PHARM KG (DE) 2001-10-09 US disclosed